Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2016)

Historic Asset Writedowns and Impairment for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Q2 2025 value amounting to $14.8 million.

  • Lineage Cell Therapeutics' Asset Writedowns and Impairment changed N/A to $14.8 million in Q2 2025 from the same period last year, while for Sep 2025 it was $14.8 million, marking a year-over-year increase of 238993.29%. This contributed to the annual value of $950000.0 for FY2016, which is N/A changed from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $14.8 million for Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Asset Writedowns and Impairment ranged from a high of $14.8 million in Q2 2025 and a low of $14.8 million during Q2 2025